Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.04%
#2 Audiera Audiera +19.18%
#3 Geodnet Geodnet +10.71%
#4 Ocean Protocol Ocean Protocol +8.89%
#5 The Bitcoin Bull The Bitcoin Bull +6.72%
#6 Rollbit Coin Rollbit Coin +6.51%
#7 Quack AI Quack AI +5.98%
#8 Tutorial Tutorial +5.97%
#9 Cysic Cysic +5.70%
#10 LAB LAB +5.44%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
CytoMed Therapeutics Limited CytoMed Therapeutics Limited

CytoMed Therapeutics Limited

GDTC
Classifica tra le azioni #32327
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical... CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Prezzo delle azioni
$0.88
Ultima sincronizzazione: 2026-08-17
Capitalizzazione di mercato
$10.41M
Variazione (1 giorno)
-7.26%
Variazione (1 anno)
-50.56%
Paese
SG
Scambia CytoMed Therapeutics Limited (GDTC)

Categoria

Healthcare
Rapporto P/B per CytoMed Therapeutics Limited (GDTC)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di CytoMed Therapeutics Limited, il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per CytoMed Therapeutics Limited da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE